GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

by barry-jtcir | May 22, 2025 | Press Releases

Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week...

GRI Bio to Participate in the Virtual Investor Closing Bell Series

by barry-jtcir | May 21, 2025 | Press Releases

Live webcast on Wednesday, May 28th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

by barry-jtcir | May 16, 2025 | Press Releases

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 16, 2025 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

by barry-jtcir | May 15, 2025 | Press Releases

Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24)...

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

by barry-jtcir | May 8, 2025 | Press Releases

The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds...